NTT's Data Center REIT Ends Flat In $773 Million Singapore Debut
NTT DC REIT, the global data center real estate investment trust of Japanese telecoms giant NTT Group, made a muted debut on the Singapore stock exchange Monday, despite growing investor interests in data centers amid the AI boom.
NTT DC REIT finished its first trading day unchanged at $1, giving it a market cap of roughly $1 billion. The investment trust raised $773 million in its IPO, the largest in Singapore since 2017, when Singtel's broadband unit NetLink NBN Trust launched a $1.7 billion public listing.
Among the seven cornerstone investors are Singapore's sovereign wealth fund GIC, which is the investment trust's second-largest shareholder after sponsor NTT. Other cornerstone investors include hedge funds Ghisallo Capital Management and Pinpoint Asset Management.
NTT DC REIT said it will use the proceeds to acquire 100% interest in its portfolio that includes six data centers—three in California, one in Virginia, one in Vienna and one in Singapore. The portfolio, which has a combined capacity of 90.7 megawatts, is worth about $1.6 billion.
In the 12 months through March, NTT DC REIT posted a 9% decrease in revenue to $178.7 million. It attributed the drop to the change of the anchor tenant at one of its California data centers, which resulted in a vacancy period of up to 6 months.
The investment trust's data centers generated 51% of its $12.2 million total monthly base rent from global cloud service providers and tech giants as of 2024, with the rest coming from companies renting server space. Its portfolio boasted an overall occupancy rate of 94.3%, with a weighted average lease expiry of 4.8 years.
NTT DC REIT is part of NTT Group, which is one of the world's largest data center operators with a portfolio of 91 sites providing more than 2,200 megawatts in capacity.
NTT DC REIT's IPO gave a much-needed boost to Singapore's subdued listing market. So far this year, the city-state has only seen three listings raising roughly $840 million, with more than 90% of that amount coming from NTT DC REIT's IPO.
In stark contrast, rival Hong Kong reclaimed its crown as the world's top listing venue in the first half of 2025, with 42 companies raising a total of $13.6 billion. The city's IPO revival has prompted some companies to switch their listings from Singapore, including Thai coconut water producer IFBH. MORE FROM FORBES Forbes Taiwan Billionaire Tsai's Cathay Venture Joins $152 Million Round In French AI Chip Startup SiPearl By Zinnia Lee Forbes Billionaire Chey's SK Group Partners With Amazon To Build A $5 Billion AI Data Center In Korea By Zinnia Lee Forbes Thailand's Coconut Water Giant IFBH Soars In Hong Kong IPO Debut By Zinnia Lee
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
TierPoint Parent Closes Upsized $250 Million Term Loan
ST. LOUIS, July 14, 2025 (GLOBE NEWSWIRE) -- The parent company of TierPoint – a leading, national enterprise data center company and provider of secure, connected IT platform solutions – today announced the closing of a $250 million term loan, a portion of which is a delayed draw term loan. Upsized due to strong investor interest, this facility complements TierPoint's asset-backed securitization (ABS) and variable funding notes (VFN) program. Net proceeds will be used to fund a portion of data center expansions and other growth-related capital expenditures; buy out leases at selected data centers; refresh capital drawn under the VFN; and redeem in full the Series B preferred equity. 'Our ability to continue successfully accessing the capital markets is a testament to the work of our world-class employees and the sustained growth that our company is delivering,' said TierPoint President and CFO Mary Meduski. 'That growth is fueled by robust market demand for our IT infrastructure solutions, including our market-leading colocation services for both enterprise and artificial intelligence workloads. This term loan positions us to continue capitalizing on that demand and serving our customers with excellence.' 'There is a clear market signal in the sustained improvement in financing terms and pricing that the company has attracted over time, now coupled with a flexible and sophisticated capital construct that sets TierPoint on a path to consolidate its unique advantages,' said Jason Zibarras, TierPoint Board Director and Managing Partner of Argo Infrastructure Partners, TierPoint's majority shareholder. Brice Soucy, Argo Director at TierPoint, added, 'This partnership with Apterra and our ability to attract a new group of lenders is key to supporting the next stage of TierPoint's growth during this period of accelerating market demand for TierPoint's infrastructure and capabilities.' Apterra Co-CEOs Michael Pantelogianis and Ralph Cho said, 'We are pleased to have led this term loan. The impressive investor demand reflects TierPoint's strong credit profile and robust business model.' Apterra Infrastructure Capital acted as lead arranger, sole bookrunner, and administrative agent for the transaction. CSC Delaware Trust Company is the collateral agent and depositary bank. Bank Street Group LLC and Seyfarth Shaw LLP served as advisor and counsel, respectively, to TierPoint's parent company. Milbank LLP served as counsel to Apterra. Perkins Coie served as counsel to CSC Delaware Trust. About TierPoint TierPoint ( has one of the largest and most geographically diversified U.S. enterprise data center footprints, with dozens of world-class, cloud-ready data centers in 20 markets, connected by a coast-to-coast fiber network. TierPoint provides secure, connected IT platform solutions that power the digital transformation of thousands of clients, from the public to private sectors, from small businesses to Fortune 500 enterprises. Taking an agnostic approach to helping clients achieve their most pressing business objectives, TierPoint is a champion for untangling the complexity of hybrid, multi-platform approaches to IT infrastructure, drawing on a comprehensive portfolio of services, from public to multitenant and private cloud, from colocation to disaster recovery, security, and more. About Argo Infrastructure Partners Argo Infrastructure Partners LP, founded by Jason Zibarras, is an independent fund manager with a long-term approach to infrastructure investing. Argo invests in high-quality infrastructure businesses and assets that provide essential services to their communities over their long operational lives, including investments in utilities, renewable energy, digital infrastructure, transportation assets and other long-duration infrastructure assets. Argo's investment philosophy couples sound investment return with responsible and sustainable investing. As of June 2025, Argo manages over $6.4 billion in assets on behalf of its investor partners. For more information, visit Media ContactsPete Abel, 314-720-3129, (for TierPoint)Ira Gorsky, (for Argo Infrastructure Partners)Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
SBC Medical Appoints Dr. Steven R. Cohen as Medical Strategy Advisor to Accelerate Global Expansion
IRVINE, Calif., July 14, 2025--(BUSINESS WIRE)--SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical"), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the appointment of Dr. Steven R. Cohen, a globally recognized leader in plastic and craniofacial surgery, as Medical Strategy Advisor. His appointment marks a significant step in the company's strategy to expand its global footprint and enhance its medical excellence. Dr. Cohen is the Founder of Faces+, an advanced aesthetic and reconstructive surgery center in San Diego, California. With over 30 years of clinical experience, he is widely known for his pioneering work in regenerative aesthetics, including the clinical application of fat-derived stem cells, skeletal facial aesthetic surgery, and the integration of artificial intelligence into medical innovation. Dr. Cohen is also the inventor of the internal craniofacial distraction device and LipoCube, both of which have become global standards in the field. Recognized by Newsweek as one of "America's Best Plastic Surgeons," Dr. Cohen has authored numerous scientific publications and textbooks and is a sought-after speaker at international conferences. He is also a Clinical Professor at the University of California, San Diego, and an active member of several global societies, including the American Society of Plastic Surgeons (ASPS). Following its Nasdaq listing in September 2024, SBC Medical has accelerated its global growth initiatives. With Dr. Cohen's participation, the company aims to elevate its medical quality, strengthen brand positioning in international markets, expand academic collaborations, and enhance its physician training programs—further solidifying its presence as a truly global medical group. Message from Yoshiyuki Aikawa, CEO of SBC Medical"It is a great honor to welcome Dr. Steven R. Cohen, a world-class clinician, to our team. His deep expertise and global perspective will play a transformative role in elevating our medical standards, physician education, and brand development. We look forward to his contributions as we enter a new phase of growth." Message from Dr. Steven R. Cohen"I am honored to join SBC Medical, a company that is not only expanding rapidly but also committed to innovation and patient-centered care. SBC Medical's investment in physician education and international collaboration resonates deeply with my own values. I look forward to contributing to the advancement of safer, scientifically grounded, and aesthetically refined regenerative aesthetics on a global scale." About Dr. Steven R. Cohen (Partial Profile) Board-certified in Plastic Surgery and Craniofacial Surgery Founder and Medical Director, Faces+ (San Diego, California) Clinical Professor of Plastic Surgery, University of California, San Diego Inventor of the internal craniofacial distraction device and LipoCube Recognized as one of America's Best Plastic Surgeons by Newsweek Global authority in facial reconstruction, stem cell therapy, and 3D surgical simulation Frequent keynote speaker at international academic societies; author of multiple books and peer-reviewed articles For more information about Dr. Steven R. Cohen, please visit: About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensing of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit View source version on Contacts SBC Medical Group Holdings Incorporated (Asia)Hikaru Fukui / Head of Investor Relations E-mail: ir@ Daisuke Murakami / Public Relations E-mail: pr@ ICR LLC (In the US)Bill Zima / Managing Partner Email:
Yahoo
18 minutes ago
- Yahoo
Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
New assay provides clinical research labs with an all-in-one comprehensive genomic profiling solution that delivers next-day results CARLSBAD, Calif., July 14, 2025--(BUSINESS WIRE)--Today, Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows. CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily. "We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD," said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. "This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward." The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day. "In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development," said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. "The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research." For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit *For Research Use Only. Not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit View source version on Contacts Media Contact Information:Jen CarrollPhone: (760) 583 - 8898E-mail: Jessika ParryPhone: 419-266-4016Email: jparry@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
